12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Multaq dronedarone: Additional Phase IIIb data

The double-blind Phase IIIb PALLAS trial in 3,236 patients showed that a significantly greater number of patients who received Multaq (n=1,619) experienced a composite of stroke, systemic arterial embolism, MI or cardiovascular death, a co-primary endpoint, vs. placebo (n=1,617; 43 vs. 19 patients, p=0.002). On the other co-primary endpoint, a significantly greater number of patients who received Multaq experienced a composite of cardiovascular hospitalization or death from any cause vs. placebo (127 vs. 67 patients, p<0.001). There were 21 deaths due to...

Read the full 386 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >